Plinabulin in combination with G-CSF is being developed for the prevention of chemotherapy-induced neutropenia (CIN) in patients with solid tumours receiving myelosuppressive chemotherapy with docetaxel, doxorubicin, and cyclophosphamide (TAC). Neutropenia is a condition associated with low levels of neutrophils, a type of white blood cell, which is a common side effect of cancer treatment. Severe neutropenia can lead to life-threatening complications due to resulting infections, and cause reduction or delay of chemotherapy treatment, potentially compromising the benefit to cancer patients.
Plinabulin (administered intravenously (IV)) has both anti-cancer and neutropeniaprevention effects. It binds to and affects the function of the protein, tubulin, within body cells, ultimately leading to cancer cell death. Plinabulin also boosts the number of cells in the bone marrow that are the source of mature immune cells in the blood, including neutrophils. If licensed, plinabulin in combination with G-CSF will offer an additional treatment option for preventing CIN in patients with solid tumours receiving myelosuppressive chemotherapy with TAC.